BPC-157
Body Protection Compound-157
Checked Oct 28, 2026
GROUND TRUTH PEPTIDES · PEPTIDE FACTS
BPC-157
Evidence grade for: Healing tendon, ligament and muscle injuries (injected)
No human evidence yet
- AProven
- BHuman trial
- CEarly data
- DNo human data
Best case for any use: B, Ulcerative colitis by rectal enema (one randomized trial, meeting abstract only).
CLAIMED, NOT PROVEN
People inject or swallow it for tendon, ligament, joint and muscle injuries, for gut complaints, and for general recovery.
WHAT HAS BEEN SHOWN
Grade D for healing tendon, ligament and muscle: no human trial has tested that, only animal work and an uncontrolled 16-person knee-pain chart review.
FDA STATUS
Not FDA approved for any use. A July 23, 2026 advisory panel vote and an HHS draft policy (Oct 30, 2026) concern pharmacy compounding only. FDA staff recommended against listing it.
RISK
No serious adverse events were reported in the roughly 30 people in published reports, but that is far too few people and too short a follow-up to detect anything but common, acute harms.
DOSE
Not on this card. See the full page.
PLACEBO
No controlled trial exists for the injected tendon, joint or oral gut uses, so a placebo effect cannot be ruled out; the one randomized trial, an ulcerative colitis enema study reported only as an abstract, did not show a clear difference from placebo (the confidence interval crossed zero).
Information, not medical advice. Talk to a licensed clinician before you act on it. Checked 2026-10-28. groundtruthpeptides.com
Watch it in 80 seconds
The Peptide Rescue Crew. Same sourced facts as this page for BPC-157, no dose on screen.
Read the video
Ground Truth presents: The Peptide Rescue Crew. Meet Dave. Dave tore his shoulder doing something he saw online. Now Dave has heard about BPC-157. BPC-157 is a short chain of amino acids. In animal and cell studies it appears to switch on a receptor called VEGFR2, which helps grow new blood vessels. That is the claimed path to faster healing, and it rests on animal work. For tendon, ligament and muscle, no controlled human trial. The human signal is a knee pain chart review of sixteen people, with no comparison group. One randomized trial in fifty three people with ulcerative colitis, by enema, showed no clear difference from placebo. No FDA approval for any use. Our grade for healing tendon, ligament and muscle is D. Animal and lab work only, no human evidence yet. The best case for any use is B, ulcerative colitis, from one trial. Here is the scorecard. The grade is D. No blood test shows if it is working, so you judge it by pain and function. About thirty people appear in the reports with no serious events, far too few to rule much out. The theory: new vessels could feed a tumor. Not FDA approved. A vial runs about forty two dollars, by our estimate. Dave is still waiting on the human trials. Information, not medical advice.
We tried it. This is what happened.
- BPC-157 and TB-500: why I stopped the two I trusted most PausedThey were my first two. They carried me through a hernia and a laser recovery. Then I stopped, because nothing I could measure said keep going.
The full answer: what it is for, the dose, the units
What people take it for: People inject or swallow it for tendon, ligament, joint and muscle injuries, for gut complaints, and for general recovery.
Does it work for healing tendon, ligament and muscle injuries (injected)? D, no human evidence yet. Result: not tested in humans.
Grade D for healing tendon, ligament and muscle: no human trial has tested that, only animal work and an uncontrolled 16-person knee-pain chart review. The best human test is a randomized ulcerative colitis enema trial reported only as a meeting abstract, with no clear difference from placebo.
No approval for any use.
Highest evidence for any use: B for ulcerative colitis by rectal enema (one randomized trial, meeting abstract only).
Safety: C, thinly characterized. No serious adverse events were reported in the roughly 30 people in published reports, but that is far too few people and too short a follow-up to detect anything but common, acute harms.
Do not use if: Active or suspected malignancy (theoretical angiogenesis risk). Untested in pregnancy.
Could it be placebo? No controlled trial exists for the injected tendon, joint or oral gut uses, so a placebo effect cannot be ruled out; the one randomized trial, an ulcerative colitis enema study reported only as an abstract, did not show a clear difference from placebo (the confidence interval crossed zero).
The dose people use, and the units to draw
No human dose-finding study exists and no trial tested a subcutaneous or oral dose. Published human studies used 2 to 4 mg into the knee, 10 mg into the bladder, 10 and 20 mg by IV and 80 mg as an enema; on the Huberman Lab episode with Dr. Abud Bakri, the typical injected amount people use was described as 100 to 200 mcg a day.
| Source | Dose | How often and how | Who it was for | Link |
|---|---|---|---|---|
| FDA briefing document, Appendix 1 (Ruenzi et al. 2005) | 80 mgUse this dose | Rectal enema once daily for 2 weeks, randomized 1:1 to BPC-157 or placebo | 53 adults with mild to moderate ulcerative colitis (46 completed); meeting abstract only | Appendix 1, pp. 54-55; summary list in Clinical Studies Assessing Safety, p. 42 |
| FDA briefing document, Appendix 1 (Veljaca et al. 2002, 2003) | 0.25, 0.5, 1 and 2 mg/kg | Rectal enema, single dose, then a one-week washout, then once daily for 7 days; placebo-controlled | 32 healthy volunteers randomized (24 received BPC-157); meeting abstracts | Appendix 1, p. 54 |
| Lee & Padgett 2021, intra-articular knee-pain chart review (dose from FDA briefing document) | 2 to 4 mg | Intra-articular injection, 1 to 2 doses, alone or with thymosin beta-4 | 17 knee-pain patients identified, 16 reached by phone; retrospective, no control group, run at the authors' own clinic | FDA briefing Appendix 1, p. 54 (dose); PubMed abstract (design and results) |
| Lee et al. 2024, interstitial cystitis pilot | 10 mg total (1 mg at each of 10 sites) | Intravesical injection into the bladder wall during a single cystoscopy | 12 women with moderate to severe interstitial cystitis; single arm, no control group, one private clinic | PubMed abstract (10 mg total, single procedure); FDA briefing Appendix 1, p. 55 (1 mg at 10 sites) |
| Lee & Burgess 2025, intravenous safety pilot | 10 mg on day 1, 20 mg on day 2 | IV infusion over one hour in 250 mL saline, on two consecutive days | 2 adults, both of whom had received IV BPC-157 before; safety only, no efficacy outcome | abstract, Methods and Results |
| ClinicalTrials.gov NCT02637284 (oral Phase 1, as described in the FDA briefing document) | Planned: 1, 3 or 6 mg single oral tablet; then 3 mg every 8 hours for 2 weeks | Oral tablet, placebo-controlled design | 42 healthy volunteers planned; no results posted and no published study, so this is a design, not a finding | p. 42, final paragraph of section c |
| Huberman Lab, "Peptides: The Science, Uses & Safety" with Dr. Abud Bakri (Jun 1, 2026) | 100 to 200 mcg per day, described as what most people inject | Injection, daily, as described in conversation; said to come from what people do, with no human dose-finding study behind it | People self-administering; the hosts state the human dose is unknown | chapter 00:19:27 and chapter 00:54:19; the page transcript has no per-line timestamps, so verify the exact minute by ear |
| Huberman Lab episode with Dr. Abud Bakri (Jun 1, 2026), Dr. Huberman's own use | About 200 mcg, one local injection ("I think") | Single injection into the upper trapezius, then stopped after the pain resolved | One person's account, not a trial | chapter 00:54:19; verify the exact minute by ear |
| The Peter Attia Drive #387, AMA #83 (Apr 13, 2026) | No dose stated | Show notes list a BPC-157 case study segment and a review of the human evidence | Attia places BPC-157 in his lowest-evidence bucket | show notes, 57:45 and 1:03:15 |
From 100 to 200 mcg a day (what Huberman Lab described people injecting, with no human trial behind it) up to 80 mg per enema (the Ruenzi 2005 ulcerative colitis trial); no human study tested a subcutaneous or oral dose.
Dose ranges printed on this site before had no named non-seller source and are removed; the figure once attributed to Dr. Bakri traced only to a machine-generated Huberman Lab AI answer, not to his words in the episode transcript. Examine could not be opened (HTTP 429) so no Examine row is given, and the Attia public notes state no dose.
Reported by the named source, never prescribed by us.
How many units do I draw?
Use the calculator: units on the syringe = dose in mcg divided by mcg per unit, where mcg per unit = (vial mg x 1000) divided by (water mL x 100). Open the dose calculator
Why it might work
- BPC-157
- VEGFR2 ↑receptor
- Angiogenesis + NOnew vessels
- Tissue repairassumed
Assumed pathway, not shown in people.
Assumed, not proven in humans: BPC-157 appears to drive healing by upregulating VEGFR2, a receptor that triggers new blood-vessel growth, and nitric-oxide signaling, while protecting the gut lining. This is well-documented in animal cells and tissue; whether it does the same at these doses in people is untested.
The trials, claim by claim
Result tags: the letter says how far human testing got for that use; the tag says what the trials found. For BPC-157 the colitis enema trial is tagged mixed because it was reported only as a meeting abstract and the confidence interval crossed zero.
Speeds healing of tendon, ligament and muscle.
Result: not tested in humans
The healing data is overwhelmingly rodent. The only human signal is a 2021 case series. 16 knee-pain patients, 87.5% reporting meaningful relief at 6-12 months, with no placebo arm and no blinding. Encouraging, not controlled.
Lee & Padgett 2021, knee-pain case series (uncontrolled, n=16)Protects and repairs the gut lining.
Result: mixed
A 2024 interstitial-cystitis pilot in 12 patients reported 80-100% symptom resolution, again uncontrolled. The mechanism rests on strong animal mucosal-protection and ulcer-healing data. A randomized, double-blind, placebo-controlled enema trial in 53 people with ulcerative colitis, reported only as a meeting abstract, did not show a clear difference from placebo.
Lee et al. 2024, interstitial-cystitis pilot (n=12)No serious adverse events observed in humans.
A 2025 IV-safety pilot dosed two healthy adults up to 20 mg IV with no adverse events and no measurable change in cardiac, liver, kidney, thyroid or glucose markers. Reassuring, but n is roughly 30 across all human reports combined.
Lee & Burgess 2025, IV safety pilot (n=2)Works orally for gut-specific goals.
Result: not tested in humans
Oral use rests on animal data showing BPC-157 survives gastric acid and acts on the gut directly. No human oral pharmacokinetic data is published.
Xue et al. 2004, intragastric BPC-157 heals gastric ulcer (rat)A randomized, placebo-controlled trial in ulcerative colitis exists, but only as an abstract.
Result: mixed
A randomized, double-blind, placebo-controlled enema study in 53 people with mild to moderate ulcerative colitis was reported as a 2005 meeting abstract only; the between-group difference had a confidence interval that crossed zero. FDA's July 2026 review judged it inadequate to support efficacy or safety. Rectal route, not the injected or oral use people buy it for.
FDA briefing document, BPC-157 (Ruenzi et al. 2005 abstract)Risks and the label warnings
Adverse events
None reported across roughly 30 humans in the published reports. FDA's July 2026 review found three post-marketing reports (an injection-site reaction, shortness of breath, and skin and gum darkening on rechallenge with a BPC-157 plus TB-500 product), none tied to BPC-157 alone. Far too few people to detect anything but common, acute harms.
Contraindications
Active or suspected malignancy (theoretical angiogenesis risk). Untested in pregnancy.
Theoretical concerns
BPC-157 upregulates VEGF and promotes angiogenesis, new blood-vessel growth, the same pathway tumors use to feed themselves. The leading clinical authority, Dr. Abud Bakri, advises cancer screening before use and warns against continuous indefinite dosing.
What nobody knows yet
No long-term human safety data of any kind. No fully published modern randomized efficacy trial supports the marketed injected or oral uses (a 53-person randomized enema trial in ulcerative colitis exists only as a meeting abstract). Optimal dose, route and cycling are all unestablished.
What else could explain the result
When someone credits BPC-157 for a recovery, ask what else changed. Most tendinopathies improve with rest and load management alone; many users simultaneously run TB-500, a structured rehab program, or TRT. The peptide almost never gets a clean attribution.
Is the vial what it says?
BPC-157 is injected, so demand a recent third-party Certificate of Analysis for the exact batch: HPLC purity ≥98%, mass-spec identity confirmation, and an LAL endotoxin result (endotoxin is invisible to HPLC and signals poor hygiene). Use an independent lab, never a vendor's in-house or vendor-recommended test. Replace bacteriostatic water every 28 days and refrigerate the reconstituted vial.
Half-life and storage
Half-life: Very short. Animal pharmacokinetics show a plasma half-life of roughly 5-30 minutes (no human PK exists at all).
Once mixed: Fragile once mixed. Keep the reconstituted vial cold and dark, swirl (never shake), avoid heat, and replace the bacteriostatic water about every 28 days. The freeze-dried powder is far more stable than the solution.
What I noticed, and what people report
Case study
- BPC-157 and TB-500: why I stopped the two I trusted most PausedThey were my first two. They carried me through a hernia and a laser recovery. Then I stopped, because nothing I could measure said keep going.
What people report
Volume of reports: moderate. A real body of reports, fairly consistent.
One of the most-discussed peptides, huge volume of dosing and recovery threads.
Reports converge on tendon/joint and gut healing, but they're uncontrolled, and non-responders tend to get blamed ('you injected wrong' or 'bad product').
First-page search is affiliate funnels; the honest signal lives on independent logs (MESO-Rx) and skeptics framing it as 'n-of-1, wild west.'
- Tendon, joint, and soft-tissue recovery is the most-reported use, many describe faster return from nagging injuries.
- Gut, reflux, and IBD-type relief is the second big cluster of reports.
- Side effects are reported as rare and mild; the most common 'complaint' is simply 'I'm not sure it did anything.'
- Reports skew positive, but it's almost always run alongside rest, rehab, or other compounds, so clean attribution is rare.
Reports are anecdote, not proof.
Can you tell if it is working?
No objective tracker exists, BPC-157's effect is local tissue repair, judged clinically (function, pain, imaging/endoscopy), not by any blood, wearable, or scan readout.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
BPC-157 acts locally at the injury/gut site via VEGFR2-driven angiogenesis and nitric-oxide signaling, with a plasma half-life under ~30 minutes; its effect is tissue repair at the site, not a systemic shift, so no analyte on a routine panel tracks whether it is working.
Read this before you spend on labs
Routine bloodwork cannot confirm BPC-157 is working. Its benefits are local tissue and gut healing plus subjective outcomes (pain, mobility, GI symptoms) that do not produce a measurable change in any orderable LabCorp/Quest panel. The registered Phase I trial is an oral safety/PK study in healthy volunteers (NCT02637284); it was designed to detect harm, not efficacy, and no routine analyte was validated as an efficacy readout. There is no independently replicated human efficacy evidence. Judge progress clinically (function, pain, imaging, endoscopy for GI cases), not by blood. Do not order a lab expecting it to prove response.
Bottom line
BPC-157 has no validated objective efficacy tracker in any modality. It acts locally at the injury or gut site via VEGFR2-driven angiogenesis and NO signaling, with a plasma half-life under ~30 minutes, so its effect is tissue repair at the site rather than a systemic shift that any analyte, wearable, CGM, DEXA, or scan would register. Human evidence is limited to a few small uncontrolled case series (tendon/ligament Grade D, gut Grade C) with no standardized objective outcome measures and no completed controlled trial. Track progress the same way the clinical data does: function, pain, range of motion, and where relevant imaging or endoscopy for the specific injury or GI lesion, not a number on a panel or a device. Anyone claiming a biomarker confirms it is guessing.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.
How to track itHistory
First documented human use: No peer-reviewed controlled human trial exists. Two early-2000s meeting abstracts describe randomized, placebo-controlled rectal-enema studies, one in healthy volunteers and one in 53 people with ulcerative colitis, never published in full. A Phase I oral trial (NCT02637284) was registered in December 2015 and never posted results. The first published human reports are uncontrolled, led by a 2021 case series of 16 knee-pain patients from a single research group.
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. The vote: 8-6, with one abstention. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. As of November 2, 2026, FDA has not published a proposed rule and this is not on the 503A Bulks List. Separately, HHS published a draft enforcement-discretion policy in the Federal Register on October 30 (docket HHS-OASH-2026-0496) that says HHS does not intend to act against pharmacies that compound certain single-ingredient peptides under conditions. The notice itself says compounded drugs are not FDA-approved. That is enforcement discretion: a draft, not a rule, not approval, and not a ruling that the compound works, and HHS can revise it. The list of named peptides and routes sits in an appendix we could not open, so which peptides it names is as press and law firms report it, not as we read it. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: it was reconstituted with recent appointees, and several work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote tallies as reported by the press (STAT, McDermott Will and Schulte); FDA has not posted tallies, minutes or a transcript, and its meeting materials are on its meeting page. Rechecked November 2, 2026 against FDA and Federal Register primary pages: FDA has published no proposed rule, docket FDA-2025-N-6895 closed July 22, 2026, and HHS published a draft enforcement-discretion policy in the Federal Register on October 30, 2026 (docket HHS-OASH-2026-0496). Nothing here is final, so check the current policy and rule before acting.. FDA, PCAC meeting, July 23-24 2026
- early 1990sIsolated and characterized from a protein in human gastric juice by Predrag Sikiric's group in Zagreb, still the primary BPC-157 research lineage.
- 2005Randomized, double-blind, placebo-controlled enema trial in 53 people with ulcerative colitis reported as a meeting abstract; never published in full.
- 2015Phase I oral trial (NCT02637284) registered, 42 healthy volunteers planned; status listed as unknown, no results ever posted.
- Sept 2023FDA places BPC-157 in Category 2, restricting bulk compounding.
- 2021-2025Three small uncontrolled human reports appear: knee pain (16), interstitial cystitis (12), IV safety (2).
- Apr 2026Dropped from Category 2 after its nominators withdrew their nominations. Not placed in any other category.
- Jul 23 2026PCAC voted 8-6 (1 abstention) to recommend BPC-157 for addition to the 503A Bulks List. Evaluated for ulcerative colitis; FDA staff recommended against. Advisory only: no FDA proposed rule as of Oct 12 2026, and no evidence grade moves on a compounding vote.
All sources
- Vasireddi et al. 2025, systematic review of BPC-157 in orthopaedic sports medicine (HSS J)
- McGuire et al. 2025, narrative review of BPC-157 for musculoskeletal healing
- Phase I oral trial, no results posted. ClinicalTrials.gov NCT02637284
- FDA briefing document for the July 23-24, 2026 advisory committee: BPC-157(Human-study table and adverse-event review)
- Dr. Abud Bakri, clinical authority
- FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 23, 2026, Appendix 1 table, Ruenzi et al. 2005 row(dose table)
- FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 23, 2026, Appendix 1 table, Veljaca et al. 2002/2003 row(dose table)
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435. The abstract gives no dose; the 2 to 4 mg range is from FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 23, 2026, Appendix 1.(dose table)
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560. Dose per site from FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 23, 2026, Appendix 1.(dose table)
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143.(dose table)
- FDA briefing document, BPC-157, Pharmacy Compounding Advisory Committee, July 23, 2026, Clinical Studies Assessing Safety(dose table)
- Huberman Lab, episode with Dr. Abud Bakri, Jun 1, 2026, chapter "Adverse events, trials, legal status" (00:19:27) for the 100 to 200 mcg statement and the 80 mg enema comparison; chapter "BPC-157 healing and patient experiences" (00:54:19) for "We don't know what the human dose is"(dose table)
- Huberman Lab, episode with Dr. Abud Bakri, Jun 1, 2026, chapter "BPC-157 healing and patient experiences" (00:54:19)(dose table)
- The Peter Attia Drive #387, AMA #83, show notes: "Peptide case study: BPC 157" at 57:45 and "BPC 157 continued: review of human evidence" at 1:03:15. Full episode is members-only; the public notes state no dose.(dose table)
Not medical advice. Grades reflect the evidence as of the date above and will change as data arrives. Reports from users are anecdote, not proof. Talk to a licensed clinician before you act on anything here.